Allogene Therapeutics, Inc.
NASDAQALLO just delivered its Q1 2026 results, and the headline number came in better than feared. EPS landed at -$0.18, a penny ahead of the -$0.19 consensus. The stock is up about 6% on the week at $2.30. Yet short sellers have been moving in the opposite direction — adding exposure at a pace not seen in months. That divergence between a modest beat and accelerating short interest is…
Snapshot as of 28 Jun 2026
ALLO just delivered its Q1 2026 results, and the headline number came in better than feared. EPS landed at -$0.18, a penny ahead of the -$0.19 consensus. The stock is up about 6% on the week at $2.30. Yet short sellers…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALLO — free to start on ORTEX.
Sign up for free →Open ALLO on ORTEX